Patients' and health professionals' attitudes and perceptions towards the initiation of preventive drugs for primary prevention of cardiovascular disease: protocol for a systematic review of qualitative studies.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
11 04 2019
Historique:
entrez: 13 4 2019
pubmed: 13 4 2019
medline: 10 4 2020
Statut: epublish

Résumé

Lipid-lowering drugs and antihypertensive agents can be prescribed for the primary prevention of cardiovascular disease. In some cases, patients eligible for primary prevention of cardiovascular disease according to the European guidelines are not always started on preventive drugs. Existing research explores the attitudes of health professionals and patients towards cardiovascular preventive drugs but does not always differentiate between the attitudes towards drug initiation for primary or secondary prevention. We aim to systematically review qualitative studies assessing health professionals' and patients' attitudes and perceptions towards drug initiation for primary prevention of cardiovascular disease. MEDLINE, MEDLINE In Process, EMBASE, PsycINFO, CINAHL, Applied Social Sciences Index and Abstracts, Conference Proceedings Citation Index (Web of Science), Healthcare Management Information Consortium, and Open Grey will be searched without restrictions on date or language of publication. Searches will be limited to studies of qualitative design, standalone or in the context of a mixed-method design, focusing on cardiovascular drug initiation for primary prevention. The primary outcome is the attitudes of health professionals and patients towards drug initiation for primary prevention of cardiovascular disease. Two reviewers will independently carry out the study selection, data extraction and quality assessment. The Critical Appraisal Skills Programme Qualitative Research Checklist will be used to assess the quality of included studies. The findings will be analysed using Thomas and Harden's thematic synthesis approach. This systematic review does not require ethical approval as primary data will not be collected. The results of the study will be published in a peer-reviewed journal and presented at relevant conferences. CRD42018095346.

Identifiants

pubmed: 30975677
pii: bmjopen-2018-025587
doi: 10.1136/bmjopen-2018-025587
pmc: PMC6500290
doi:

Substances chimiques

Antihypertensive Agents 0
Hydroxymethylglutaryl-CoA Reductase Inhibitors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e025587

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Br J Gen Pract. 2015 Aug;65(637):e538-44
pubmed: 26212850
Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004816
pubmed: 23440795
BMJ Open. 2018 Mar 22;8(3):e019965
pubmed: 29567850
Qual Health Res. 2012 Oct;22(10):1435-43
pubmed: 22829486
Heart. 2008 Oct;94(10):1331-2
pubmed: 18701534
BMC Health Serv Res. 2014 Sep 20;14:414
pubmed: 25240604
PLoS Med. 2016 Nov 15;13(11):e1002169
pubmed: 27846215
JAMA. 2016 Nov 15;316(19):2008-2024
pubmed: 27838722
Br J Gen Pract. 2003 Sep;53(494):684-9
pubmed: 15103875
Atherosclerosis. 2016 Sep;252:207-274
pubmed: 27664503
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
BMC Med Res Methodol. 2012 Nov 27;12:181
pubmed: 23185978
Lancet. 2017 Mar 11;389(10073):1055-1065
pubmed: 28290995
Br J Gen Pract. 2007 Dec;57(545):971-8
pubmed: 18252073
BMC Health Serv Res. 2008 Oct 22;8:218
pubmed: 18945360
Curr Opin Cardiol. 2012 Sep;27(5):533-41
pubmed: 22820103
BMC Fam Pract. 2011 Jun 26;12:59
pubmed: 21703010
Bull World Health Organ. 2014 Jan 1;92(1):10-19C
pubmed: 24391296
PLoS One. 2018 Feb 8;13(2):e0191817
pubmed: 29420613
Eur J Gen Pract. 2007;13(1):27-34
pubmed: 17366291
BMC Med Res Methodol. 2008 Jul 10;8:45
pubmed: 18616818
JAMA Cardiol. 2016 Jun 1;1(3):341-9
pubmed: 27438118
Heart. 2014 Apr;100 Suppl 2:ii1-ii67
pubmed: 24667225
Arch Intern Med. 2006 Nov 27;166(21):2307-13
pubmed: 17130382
PLoS One. 2013 Jul 26;8(7):e67611
pubmed: 23922649
J Gen Intern Med. 2014 May;29(5):723-31
pubmed: 24493322
BMJ Open. 2016 May 13;6(5):e010458
pubmed: 27178972
Br J Gen Pract. 2018 Jun;68(671):e408-e419
pubmed: 29784867
BMJ. 2008 Jun 28;336(7659):1475-82
pubmed: 18573856

Auteurs

Olla Qadi (O)

Institute of Applied Health Research, University of Birmingham, Birmingham, West Midlands, UK.

Tom Marshall (T)

Institute of Applied Health Research, University of Birmingham, Birmingham, West Midlands, UK.

Nicola Adderley (N)

Institute of Applied Health Research, University of Birmingham, Birmingham, West Midlands, UK.

Danai Bem (D)

Institute of Applied Health Research, University of Birmingham, Birmingham, West Midlands, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH